Physician profile
Paul M Mann
NPI 1467440909
$74,993.00
in general payments reported to CMS, 2019-2025
34 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,205 · 2020: $6,118 · 2021: $4,846 · 2022: $7,209 · 2023: $42K · 2024: $8,456 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $6,664 · Education: $72.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,378.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $6,663.74 |
| Education | $72.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $38,535.96 | 2019-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $22,825.81 | 2019-2025 | Precision 1, Dailies Total1, Air Optix Color |
| Aesculap, INC. | $4,617.07 | 2020 | |
| Abbvie INC. | $1,481.99 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,372.36 | 2019-2025 | Cequa |
| Allergan, INC. | $1,201.51 | 2019-2022 | |
| Carl Zeiss Meditec Cataract Technology INC. | $604.72 | 2020-2023 | |
| Carl Zeiss Meditec, INC. | $596.01 | 2020 | |
| Novartis Pharmaceuticals Corporation | $521.49 | 2020-2022 | |
| Oyster Point Pharma, INC. | $390.33 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $350.39 | 2023-2025 | Xiidra, Miebo |
| Biotissue Holdings INC. | $297.43 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $292.32 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $278.18 | 2019-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $184.53 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $167.27 | 2024-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| New World Medical,INC. | $165.18 | 2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Lensar, INC. | $157.58 | 2022 | |
| Heidelberg Engineering, INC. | $128.52 | 2019 | |
| Glaukos Corporation | $125.97 | 2022 | |
| Shire North American Group INC | $125.15 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $84.60 | 2025 | |
| Harrow Eye, LLC | $80.26 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $68.39 | 2021 | |
| Eyevance Pharmaceuticals LLC | $62.10 | 2019-2021 | |
| Leica Microsystems INC. | $54.47 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.97 | 2019 | |
| Genentech USA, INC. | $42.28 | 2020-2025 | Vabysmo |
| Beaver-Visitec International, INC. | $39.91 | 2019-2021 | |
| Amgen INC. | $30.47 | 2024 | Tepezza |
| Coopervision INC. | $26.11 | 2022 | |
| Aerie Pharmaceuticals, INC. | $24.60 | 2020 | |
| Topcon Healthcare Solutions, INC. | $13.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.